Early access treatment for steroid-resistant gut graft-versus-host disease
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This program provides early access to an experimental treatment called MaaT013 for people with severe gut graft-versus-host disease that has not improved with steroids. It aims to help control the condition when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have severe (grade III or IV) gut graft-versus-host disease, with or without other organ involvement.
- Your condition has not responded to steroids and at least one other treatment.
- You cannot reduce your steroid dose without your condition getting worse.
- You do not have an active uncontrolled infection or other serious complications like bowel blockage or perforation.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a fecal transplant (a procedure that transfers healthy bacteria from a donor's stool into your gut) can help children whose gut graft-versus-host disease (a common complication after a stem cell transplant) is not improving with standard steroid treatment.
This study is testing an investigational cell therapy called NCR102 for people who have severe graft-versus-host disease (a complication after a stem cell transplant) that mainly affects the gut and has not responded to standard treatments. The goal is to see if this new approach is safe and can help control the disease.
This study tests whether adding an investigational drug called Amimaitosai to standard steroids helps control gut symptoms caused by graft-versus-host disease after a stem cell transplant. It may offer a new option to reduce these symptoms and improve recovery.
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
Hear when a new Acute Graft Versus Host Disease in Intestine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.